Torsemide

Torsemide Tablets 20 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Torsemide / Torasemide Tablets (5mg, 40mg) is a long-acting pyridine-sulfonylurea loop diuretic on the WHO Model List framework. It inhibits the Na+/K+/2Cl- carrier system in the thick ascending limb of Henle's loop, blocking active sodium and chloride reabsorption. It features high oral bioavailability (~80%), consistent absorption regardless of intestinal mucosal edema, and an extended duration of action (~12 hours) with anti-aldosteronergic properties that cause less potassium wasting than furosemide. Indicated for treatment of edema associated with congestive heart failure, chronic kidney disease (CKD), nephrotic syndrome, hepatic cirrhosis, and management of hypertension.

Torsemide / Torasemide Tablets (5mg, 40mg) is a long-acting pyridine-sulfonylurea loop diuretic on the WHO Model List framework. It inhibits the Na+/K+/2Cl- carrier system in the thick ascending limb of Henle's loop, blocking active sodium and chloride reabsorption. It features high oral bioavailability (~80%), consistent absorption regardless of intestinal mucosal edema, and an extended duration of action (~12 hours) with anti-aldosteronergic properties that cause less potassium wasting than furosemide. Indicated for treatment of edema associated with congestive heart failure, chronic kidney disease (CKD), nephrotic syndrome, hepatic cirrhosis, and management of hypertension.

Torsemide Tablets 100mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Combikit of Eplerenone Tablets 25mg + Torsemide Tablets 10mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Combi Kit of Torasemide (20mg) Tablets and Eplerenone (25mg) Tablets combines a long-acting loop diuretic with a selective mineralocorticoid receptor antagonist (MRA). Torasemide delivers potent, predictable loop diuresis with minimal urinary potassium wasting compared to furosemide. Eplerenone selectively blocks aldosterone without binding to androgen or progesterone receptors, completely eliminating gynecomastia and sexual side effects while preventing hypokalemia. Indicated for severe edema, chronic heart failure with reduced ejection fraction (HFrEF), and refractory hypertension.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.